我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的隐私政策。
相关临床试验
0
0 进行中
药物批准
批准总数
监管机构
监管机构数
成立时间
N/A
暂无试验阶段数据
暂无试验数据
暂无批准数据
- Pembrolizumab plus lenvatinib demonstrated a 50% overall response rate in treatment-naive non-clear cell RCC, leading to FDA approval and NCCN recommendation. - Cabozantinib plus nivolumab showed a 54% overall response rate in a phase 2 trial, supporting its use in non-clear cell RCC, even with prior therapy in some patients. - Both IO/TKI combinations exhibit manageable adverse event profiles, with common toxicities including hypertension, diarrhea, and hand-foot syndrome. - Dose adjustments and interruptions are crucial for managing toxicities and maintaining patients on treatment, potentially improving long-term outcomes.
